Some biopharma business development teams had a sleepless weekend. Four healthcare-related acquisitions were announced in quick succession on Monday morning, totaling about $18 billion …
After an incredible run, investors are finally seeing some pain in the biotech and broader health care sector. Major biotechnology indexes were off …
In a research report released today, Brean Capital analyst Difei Yang maintained a Buy rating on Horizon Pharma PLC (NASDAQ:HZNP) and raised the price target …
In a research report released today, Brean Capital analyst Difei Yang reiterated a Buy rating on Horizon Pharma (NASDAQ:HZNP) with a price target …
Brean Capital analyst Difei Yang initiated coverage on shares of Horizon Pharma (NASDAQ:HZNP) with a Buy rating and a price target of $18, which represents a …
